Getting Ready For SUT X-Ray Irradiation

Mapping the epigenetic and transcription factor landscape is essential for understanding gene regulatory mechanisms and holds huge potential for identification of biomarkers and targets for epigenetic therapy.

At present cancer research focuses on three major areas viz. cancer diagnostics, drugs development, and next-generation therapies. About 90% of the in-vitro research rely on traditional two-dimensional (2D) monolayer cell culture systems. 2D cell culture systems fail to accurately recapitulate the structure, function, physiology of living tissues, due to which the various studies such as assessing the efficacy of new drugs, study gene expressions, metabolic pathways, and cell proliferation do not correlate to actual In-vivo scenario.

Among many exciting precision medicine strategies, RNA-based therapeutics are rapidly growing in popularity and effectiveness. Although progress has been achieved in developing RNA-targeted delivery carriers (mainly by using monoclonal antibodies for targeting), their clinical translation has yet to be fully recognized. This is due, in no small part, to massive development and production requirements and high batch-to-batch variability of current technologies, which currently rely on chemical conjugation. Novel synthesis methodologies could help vault these therapeutic strategies into the market and patients much more quickly.

Antibody-drug conjugates (ADCs) were initially developed to provide a selective targeting mechanism for cytotoxic small molecule drugs with the goal of improving the therapeutic index in clinical practice. But despite a careful target selection and a high degree of specificity afforded through the antibody part of the ADC, a sufficiently improved therapeutic index has been challenging to achieve. It often remains a challenge to reach desirable efficacious doses with repeated cycles of treatment due to the toxicity profile induced by the cytotoxic warhead. The clinical landscape of ADC therapeutics in both hematological and solid cancers has grown in recent years considerably to nearly 600 clinical trials incorporating numerous ADC modalities. These new molecular entities utilize many different tumor-associated antigen targets, new conjugation technologies, and payload warheads of various mechanisms such as tubulin inhibitors, DNA damaging, topoisomerase inhibition, or DNA polymerase II inhibitors.